Navigation Links
Van Andel Institute and Children's Memorial Research Center of Chicago Form a Partnership to Facilitate Pediatric Research
Date:2/26/2008

XenoBase software can be used to develop more effective treatments for pediatric patients

GRAND RAPIDS, Mich., Feb. 26 /PRNewswire-USNewswire/ -- Van Andel Institute (VAI) has entered into a multi-year licensing agreement with Children's Memorial Research Center (CMRC) of Chicago for use of its XenoBase software and database system.

XenoBase is a unique, advanced bio-informatic system created by scientists at Van Andel Research Institute (VARI) to support all aspects of the life sciences from basic research discovery to clinical application. The platform holds great promise for researchers and clinicians who use the system to explore the molecular and clinical basis of disease. In recent applications, physicians have used the tool to match the molecular profile of tumors of late-stage cancer patients to the most effective therapy, based on molecular evidence.

"The XenoBase technology holds great promise for the future as we evolve toward a more proactive standard of health care," said VAI Chairman & CEO David Van Andel. "We are pleased to enter into this agreement with an internationally recognized research center under the fine leadership of Dr. Hendrix who is dedicated to producing innovative solutions to prevent, diagnose and treat diseases affecting children."

CMRC is the research arm of Children's Memorial Hospital (CMH), the pediatric teaching hospital for Northwestern University's Feinberg School of Medicine. It is one of only a handful of institutions in the United States dedicated exclusively to pediatric research. Like the researchers at VARI, the research team of CMRC will use XenoBase to explore the molecular and clinical basis for disease and to support the discovery of novel approaches to alleviate pain and suffering due to disease.

"As a result of this agreement between CMRC and VARI, we anticipate novel collaborations using XenoBase to more quickly impact human disease," said Mary J.C. Hendrix, Ph.D., Medical Research Institute Council Endowed Chair for the President and Scientific Director of CMRC.

XenoBase is the result of five years of research and development in the lab of Craig P. Webb, Ph.D., Director of VARI's Program of Translational Medicine. The system can collect and analyze a wide range of molecular and conventional clinical data to aid researchers in identifying associations between diseases, biomarkers and treatment outcomes. "We are delighted to license this technology to CMRC and demonstrate its effectiveness in supporting different areas of pediatric translational research," said Webb. "We look forward to collaborative efforts through which improved diagnostic and therapeutic strategies can ultimately be introduced to the pediatric population."

The mission of Children's Memorial Research Center is to generate new knowledge leading to advancements in the prevention, diagnosis, and treatment of diseases that affect the development of children through adolescence as well as adult disorders that derive from them. Our multidisciplinary teams of physicians, scientists, technicians, nurses and trainees are committed to making discoveries that will improve the lives of children and their families.

Established by Jay and Betty Van Andel in 1996, Van Andel Institute is an independent research organization dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process.


'/>"/>
SOURCE Children's Memorial Hospital
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. OHSU Cancer Institute research gives hope for chemo holidays for men with advanced prostate cancer
2. Otho S.A. Sprague Memorial Institute awards Rush nearly $125,000 for new patient-safety project
3. Otho S.A. Sprague Memorial Institute awards Rush $230,000 for childhood obesity prevention
4. Bishop T. D. Jakes Receives The Black Aids Institute 2008 Heroes in the Struggle Award
5. UNT Health Science Center and The Center for Cancer and Blood Disorders Collaborate on New Institute for Cancer and Blood Disorders
6. China Holdings Announces Starwood Research Institute Initiates Research Coverage
7. OHSU cancer institute researcher discovers new predictor of prostate cancer recurrence
8. Southern Research Institute Names Blaine Knight Vice President of Drug Discovery
9. VEGF Neutralization Can Damage Brain Vessels, Say Schepens Eye Research Institute Scientists
10. VEGF neutralization can damage brain vessels, say Schepens Eye Research Institute scientists
11. Dana-Farber Cancer Institute Completes Deployment of MedAptus Infusion Services Module
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... name the Creator responds to and which He does not. Yisrayl says with so ... one is the true name, but he says with a little Scripture, backed with a ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA ... region. Côté has 20+ years of experience within the beauty industry, ranging from ... an array of high-end cosmetic brands, retail brands and outlets in Canada and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation ... supplements, through its Nova Skin Sciences division, recently announced the launch of Allumière ... with the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark ...
(Date:4/28/2017)... ... ... Rob Lowe is a popular actor that has been in many different movies ... as the host of the “Informed” series. The program focuses on many important issues ... focuses on thyroid cancer. , Although thyroid cancer is an uncommon type of cancer, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Christie Medical Holdings, Inc. ... alliance with B. Braun Medical Inc. , a leader in infusion therapy and ... with as many as 90 percent of hospital patients receiving a peripheral IV catheter ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... from the Company,s consumer product development program, based ... the Society for Investigative Dermatology (SID) 76 th ... advance and promote the sciences relevant to skin ...
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
Breaking Medicine Technology: